{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Alnylam to Webcast TTR Investor Webinar - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"YojVzlyfef\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/\">Alnylam to Webcast TTR Investor Webinar<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/embed\/#?secret=YojVzlyfef\" width=\"600\" height=\"338\" title=\"&#8220;Alnylam to Webcast TTR Investor Webinar&#8221; &#8212; Market Newsdesk\" data-secret=\"YojVzlyfef\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Alnylam to Webcast TTR Investor Webinar CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company\u2019s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA\u00ae in ATTR-CM, will highlight Alnylam\u2019s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company\u2019s flagship TTR franchise. The webinar will feature Alnylam\u2019s senior commercial and medical leaders, including: Tolga Tanguler \u2013 Chief Commercial Officer John Kennedy &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}